Entera Bio (NASDAQ:ENTX - Get Free Report) was upgraded by investment analysts at Wall Street Zen from a "strong sell" rating to a "sell" rating in a research note issued to investors on Saturday, Wall Street Zen reports.
Other equities analysts have also recently issued reports about the company. Lifesci Capital started coverage on Entera Bio in a report on Wednesday, September 23rd. They issued an "outperform" rating and a $10.00 target price for the company. Cantor Fitzgerald started coverage on Entera Bio in a research note on Tuesday, September 22nd. They issued an "overweight" rating for the company. Leerink Partners began coverage on shares of Entera Bio in a report on Friday, September 18th. They issued an "outperform" rating and a $9.00 price objective on the stock. UBS Group set a $9.00 target price on Entera Bio in a report on Friday, September 18th. Finally, Guggenheim assumed coverage on shares of Entera Bio in a research report on Thursday, September 24th. They issued a "buy" rating and a $11.00 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $9.60.
Get Our Latest Analysis on Entera Bio
Entera Bio Stock Up 0.9%
Shares of NASDAQ ENTX opened at $3.31 on Friday. The business's 50 day moving average is $2.93 and its two-hundred day moving average is $2.03. The company has a market cap of $576.40 million, a P/E ratio of -8.49 and a beta of 1.48. Entera Bio has a 12 month low of $0.91 and a 12 month high of $4.20.
Entera Bio (NASDAQ:ENTX - Get Free Report) last released its earnings results on Friday, November 6th. The company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($0.05). Sell-side analysts expect that Entera Bio will post -0.40 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
A number of institutional investors have recently made changes to their positions in the business. Logos Global Management LP acquired a new stake in Entera Bio during the 3rd quarter valued at $12,838,000. RA Capital Management L.P. bought a new position in Entera Bio during the third quarter worth $14,265,000. Marshall Wace LLP acquired a new position in shares of Entera Bio in the third quarter valued at $613,000. Nantahala Capital Management LLC acquired a new position in shares of Entera Bio in the third quarter valued at $8,744,000. Finally, Seven Fleet Capital Management LP raised its position in shares of Entera Bio by 51.9% in the first quarter. Seven Fleet Capital Management LP now owns 205,542 shares of the company's stock valued at $228,000 after purchasing an additional 70,224 shares during the period. 14.11% of the stock is owned by institutional investors and hedge funds.
Entera Bio Company Profile
(
Get Free Report)
Entera Bio Ltd. is a clinical-stage biopharmaceutical company based in Jerusalem, Israel. It develops oral peptide therapies for conditions that have traditionally been treated with injectable medicines, with a focus on bone and endocrine disorders. The company's development programs include EB613, an oral formulation of parathyroid hormone being studied for osteoporosis, and EB612, an oral parathyroid hormone candidate for hypoparathyroidism. Entera uses its proprietary oral-delivery technology to pursue the development of these therapies.
See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Entera Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Entera Bio wasn't on the list.
While Entera Bio currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.